Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Licenses Chemotherapy Management Technology from Saladax

NEW YORK (GenomeWeb News) – Myriad Genetics said today it has licensed pharmacokinetic analysis technology from Saladax Biomedical for use in chemotherapy drug management.
 
Under the agreement, Myriad has gained an exclusive North American license for Saladax technology that allows doctors to personalize chemotherapy doses to improve the efficacy of the treatment and to minimize toxicity, the company said.
 
Myriad President Gregory Critchfield said in a statement that the technology will “complement our current product portfolio and will be readily sold through our existing 150-person oncology salesforce.”
 
Financial terms of the agreement were not released.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.